170 related articles for article (PubMed ID: 12490842)
1. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors.
Cohen MS; Hussain HB; Moley JF
Surgery; 2002 Dec; 132(6):960-6; discussion 966-7. PubMed ID: 12490842
[TBL] [Abstract][Full Text] [Related]
2. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.
Skinner MA; Safford SD; Freemerman AJ
Anticancer Res; 2003; 23(5A):3601-6. PubMed ID: 14666655
[TBL] [Abstract][Full Text] [Related]
3. Re: "Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors".
Plaza Menacho I; de Groot JW; Links T; Plukker J; Eggen BJ; Hofstra R
Surgery; 2004 Feb; 135(2):240-1; author reply 241. PubMed ID: 14760839
[No Abstract] [Full Text] [Related]
4. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
[TBL] [Abstract][Full Text] [Related]
5. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
Ezzat S; Huang P; Dackiw A; Asa SL
Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effects of Src inhibition on medullary thyroid cancer.
Liu Z; Falola J; Zhu X; Gu Y; Kim LT; Sarosi GA; Anthony T; Nwariaku FE
J Clin Endocrinol Metab; 2004 Jul; 89(7):3503-9. PubMed ID: 15240638
[TBL] [Abstract][Full Text] [Related]
8. RET signals through focal adhesion kinase in medullary thyroid cancer cells.
Panta GR; Nwariaku F; Kim LT
Surgery; 2004 Dec; 136(6):1212-7. PubMed ID: 15657578
[TBL] [Abstract][Full Text] [Related]
9. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ret tyrosine kinase activity by herbimycin A.
Taniguchi M; Uehara Y; Matsuyama M; Takahashi M
Biochem Biophys Res Commun; 1993 Aug; 195(1):208-14. PubMed ID: 8363602
[TBL] [Abstract][Full Text] [Related]
11. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
Frasca F; Vigneri P; Vella V; Vigneri R; Wang JY
Oncogene; 2001 Jun; 20(29):3845-56. PubMed ID: 11439348
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines.
Farivar RS; Gardner-Thorpe J; Ito H; Arshad H; Zinner MJ; Ashley SW; Whang EE
J Surg Res; 2003 Dec; 115(2):219-25. PubMed ID: 14697287
[TBL] [Abstract][Full Text] [Related]
14. Direct phosphorylation of proliferative and survival pathway proteins by RET.
Panta GR; Du L; Nwariaku FE; Kim LT
Surgery; 2005 Aug; 138(2):269-74. PubMed ID: 16153436
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.
Ferrari SM; Fallahi P; La Motta C; Bocci G; Corrado A; Materazzi G; Galleri D; Piaggi S; Danesi R; Da Settimo F; Miccoli P; Antonelli A
Surgery; 2014 Nov; 156(5):1167-76. PubMed ID: 25151558
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids differentially inhibit expression of the RET proto-oncogene.
Capes-Davis A; Andrew SD; Hyland VJ; Twigg S; Learoyd DL; Dwight T; Marsh DJ; Robinson BG
Gene Expr; 1999; 8(5-6):311-26. PubMed ID: 10947080
[TBL] [Abstract][Full Text] [Related]
17. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
18. Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells.
Carson-Walter EB; Smith DP; Ponder BA; Baylin SB; Nelkin BD
Oncogene; 1998 Jul; 17(3):367-76. PubMed ID: 9690518
[TBL] [Abstract][Full Text] [Related]
19. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant.
Drosten M; Frilling A; Stiewe T; Pützer BM
Surgery; 2002 Dec; 132(6):991-7; discussion 997. PubMed ID: 12490846
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
